Enzymatic activities of the GB virus-B RNA-dependent RNA polymerase

• Published in: Virology (New York, N.Y.) N.Y.), 2003-08, Vol.312 (2), p.270-280
• Main Authors: Ranjith-Kumar, C.T, Santos, Jan Lee, Gutshall, Lester L, Johnston, Victor K, Lin-Goerke, Juili, Kim, Min-Ju, Porter, David J, Maley, Derrick, Greenwood, Cathy, Earnshaw, David L, Baker, Audrey, Gu, Baohua, Silverman, Carol, Sarisky, Robert T, Kao, Cheng
• Format: Article
• Language: English
• Subjects: Base Sequence; GB virus B - drug effects; GB virus B - enzymology; GBV-B; HCV; Molecular Sequence Data; Nucleotides - metabolism; RNA Replicase - antagonists & inhibitors; RNA Replicase - isolation & purification; RNA Replicase - metabolism; RNA, Viral - biosynthesis; RNA, Viral - genetics; RNA-dependent RNA polymerase; Templates, Genetic
• ISSN: 0042-6822; 1096-0341
• DOI: 10.1016/S0042-6822(03)00247-2

The GB virus-B (GBV-B) nonstructural protein 5B (NS5B) encodes an RNA-dependent RNA polymerase (RdRp) with greater than 50% sequence similarity to the hepatitis C virus (HCV) NS5B. Recombinant GBV-B NS5B was reported to possess RdRp activity (W. Zhong et al., 2000, J. Viral Hepat. 7, 335–342). In this study, the GBV-B RdRp was examined more thoroughly for different RNA synthesis activities, including primer-extension, de novo initiation, template switch, terminal nucleotide addition, and template specificity. The results can be compared with previous characterizations of the HCV RdRp. The two RdRps share similarities in terms of metal ion and template preference, the abilities to add nontemplated nucleotides, perform both de novo initiation and extension from a primer, and switch templates. However, several differences in RNA synthesis between the GBV-B and HCV RdRps were observed, including (i) optimal temperatures for activity, (ii) ranges of Mn 2+ concentration tolerated for activity, and (iii) cation requirements for de novo RNA synthesis and terminal transferase activity. To assess whether the recombinant GBV-B RdRp may represent a relevant surrogate system for testing HCV antiviral agents, two compounds demonstrated to be active at nanomolar concentrations against HCV NS5B were tested on the GBV RdRp. A chain terminating nucleotide analog could prevent RNA synthesis, while a nonnucleoside HCV inhibitor was unable to affect RNA synthesis by the GBV RdRp.